Additionally, an analysis of three large US healthcare claims databases showed no evidence of an increased cardiovascular risk among patients who had RA and switched from bDMARDs or JAK inhibitors to tocilizumab compared with those who switched to an anti-TNF-α agent [16]. This evidence concerns the gene TNF and rheumatoid arthritis.